Peer-Reviewed Publication
Eur Child Adolesc Psychiatry2025;34(9):2707-2716.September 1, 2025Journal Article
Replicating and extending the reliability, criterion validity, and treatment sensitivity of the shortened PANSS for pediatric trials.
Joan Busner1,2, Eric A Youngstrom3, Joshua A Langfus4, David G Daniel5,6, Robert L Findling7
1Signant Health, Blue Bell, PA, USA. joan.busner@signanthealth.com.
2Virginia Commonwealth University School of Medicine, Richmond, VA, USA. joan.busner@signanthealth.com.
3Nationwide Children's Hospital and The Ohio State University, Helping Give Away Psychological Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
4University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
5Signant Health, McLean, VA, USA.
6George Washington University School of Medicine, Washington, DC, USA.
7Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Abstract
Do the shortened Positive and Negative Syndrome Scale (PANSS) (Kay et al., J Clin Psychiatry 58:538-546, 1987) versions recently developed from a National Institute of Mental Health (NIMH) pediatric dataset continue to perform well in a third independent randomized double-blind clinical trial of adolescents with schizophrenia? Secondary analysis of the double-blind, placebo-controlled aripiprazole…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans